Want to see PFE full AI Analyst Report?
PFE Stock Chart & Stats
$28.57
-$0.04(-0.16%)
At close: 4:00 PM EDT
$28.57
-$0.04(-0.16%)
Day’s Range― - ―
52-Week Range$23.62 - $29.21
Previous CloseN/A
Volume28.91M
Average Volume (3M)32.65M
Market Cap
$163.69B
Enterprise Value$190.23K
Total Cash (Recent Filing)$11.70B
Total Debt (Recent Filing)$63.19B
Price to Earnings (P/E)37.5
Beta0.46
Next Earnings
Nov 03, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend Yield5.99%
Share Statistics
EPS (TTM)0.76
Shares Outstanding5,699,674,000
10 Day Avg. Volume34,768,866
30 Day Avg. Volume32,653,574
Financial Highlights & Ratios
PEG Ratio-4.33
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$28.67Price Target Upside0.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)2.97
Revenue Forecast (FY)$62.25B
Bulls Say, Bears Say
Bulls Say
Growth In Launched And Acquired ProductsStrong growth from launched and acquired products demonstrates that Pfizer is building revenue beyond its COVID portfolio. Performance from Seagen assets, Padcev, NURTEC and Eliquis supports a broader commercial base and can improve resilience as individual products approach exclusivity loss.
Pipeline Depth And Clinical MomentumThe volume of approvals, readouts and pivotal study starts indicates an active pipeline capable of replenishing the portfolio over time. Progress in oncology, obesity, immunology and ADC programs broadens future growth options and reduces reliance on mature products.
Cost Savings And Operating DisciplineA multiyear productivity program can provide durable support to margins and cash generation while Pfizer funds elevated research spending. The expanded savings target, combined with lower operational SG&A and realized manufacturing savings, creates a meaningful lever for earnings recovery.
Bears Say
Elevated Leverage During The LOE TransitionLeverage near 2.7x limits financial flexibility as Pfizer approaches loss-of-exclusivity events and faces pressure on cash flow. Maintaining or increasing debt through this transition could constrain business development, investment capacity and shareholder returns if earnings weaken.
Lower And Volatile Earnings BaseThe sharp decline from prior earnings peaks shows that Pfizer’s recent recovery has not restored historical earnings power. Volatility and a lower profit base make it harder to fund growth, absorb setbacks and sustain returns while the company replaces lost revenue.
Clinical Execution And Asset RiskThe Phase III failure highlights the risk that substantial research investment may not translate into approvals or commercial revenue. The resulting impairment also shows how clinical setbacks can reduce asset value, disrupt forecasts and leave the portfolio more dependent on other pipeline programs.
Pfizer News
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $23.62 and its highest was $29.21 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $163.69B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Nov 03, 2026 which is in 33 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Aug 04, 2026. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.682 by $0.088.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 5.99%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.76.
How many shares outstanding does Pfizer have?
Pfizer has 5,699,674,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.77 in its last earnings report, beating expectations of $0.682. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in PFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.67 (0.36% Upside)
$28.67 (0.36% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 85%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.87%
12-Months-Change
Fundamentals
Return on Equity
5.99%
Trailing 12-Months
Asset Growth
-2.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pfizer
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
PFE Company Deck
PFE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and strategic narrative: management beat Q2 revenue and adjusted EPS expectations, raised full-year revenue guidance, highlighted strong growth across launched and acquired products (notably Seagen assets, Padcev, NURTEC, and Eliquis), and outlined robust R&D progress (numerous readouts, pivotal starts and promising clinical data across obesity, oncology and immunology). At the same time, material near-term setbacks were disclosed: a Phase III SV miss that drove a $4.3 billion impairment and a GAAP loss, lower-than-expected COVID revenues (notably Paxlovid), removal of Oxbryta revenue from forecasts, and elevated near-term R&D spend. Management emphasized cost-savings initiatives (now targeting ~ $9.7B through 2029), maintained dividend commitments, and raised confidence in returning to growth by the end of the decade. Overall, positives (revenue/EPS beats, guidance raise, strong launched/acquired product growth, and significant pipeline progress) outweigh the material but specific negatives tied largely to one clinical readout and COVID variability.View all PFE earnings summariesPFE Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
PFE Stock 12 Month Forecast
Average Price Target
$28.67
▲(0.36% Upside)
Technical Analysis
Ownership Overview
0.02% Insiders
15.51% Mutual Funds
12.32% Other Institutional Investors
48.50% Public Companies and Individual Investors